Leading policy-makers and scholars explain how market forces, deregulation, and consumer choice can work to improve health care for all Americans.


Viable Vioxx
Wall Street Journal, 2-22-05

Last week the FDA advisory committee on Cox-2 drugs ruled that Vioxx should be allowed back on the market, albeit that all drugs in the same class should receive powerful label warnings about potential cardiovascular side-effects.

The Journal says that “[t]his is great news for anyone who might ever have a need for chronic pain management, or indeed an interest in a rational regulatory environment for all future drug development. And it’s a well-deserved rebuke to the nexus of trial lawyers and journalists who whipped up such disproportionate hysteria about the Cox-2s last fall.”

They also praise acting FDA Commissioner Lester Crawford, who allowed 3 days of open hearings on the issue, where everyone, including Cox-2 critics, were given a fair hearing. Ultimately, however, “decisions about the risks and benefits of Cox-2s and other drugs should almost always rest with doctors and patients, not Washington bureaucrats.”

Project FDA.
home   spotlight   commentary   research   events   news   about   contact   links   archives
Copyright Manhattan Institute for Policy Research
52 Vanderbilt Avenue
New York, NY 10017
(212) 599-7000